Effect of methylglyoxal on Parkinson’s disease pathophysiology in the rotenone model
Open Access
- 31 May 2024
- journal article
- research article
- Published by Marmara University in Marmara Medical Journal
- Vol. 37 (2) , 166-177
Abstract
Objective: Type 2 diabetes mellitus patients have been reported to have a higher incidence of Parkinson’s disease. This study aimed to explore the effect of advanced glycation end products precursor methylglyoxal (MGO) on the pathophysiology of Parkinson’s disease in a rotenone model. Materials and Methods: Adult female Wistar rats (n=42) were divided into four groups. Rotenone toxicity was assessed by daily weight measurements and mortality rates. Effect of MGO on blood glucose was evaluated. Locomotor activity, rearing, and rotarod tests were performed to evaluate motor functions, and for neurodegeneration, tyrosine hydroxylase immunoreactivity in the striatum and substantia nigra regions was assessed. Results: The mortality rate was 9% in the rotenone-applied rats. The mean weight, locomotor activity, rearing activity, and longest time spent on a rotarod were lower in the MGO+Rotenone group than in the Control group. Tyrosine hydroxylase immunoreactivity in the striatum rostral to the anterior commissure in the MGO+Rotenone group was lower than that in the Control and MGO groups. The number of tyrosine hydroxylase positive cells in the substantia nigra pars compacta was comparable among the groups. Conclusion: When nigrostriatal degeneration was triggered, MGO was found to worsen motor dysfunction and increase damage to dopaminergic neuron projections.Keywords
This publication has 51 references indexed in Scilit:
- Intranasal Exposure to Low-Dose Rotenone Induced Alpha-Synuclein Accumulation and Parkinson’s Like Symptoms Without Loss of Dopaminergic NeuronsNeurotoxicity Research, 2021
- Short-Term Alterations in Behavior and Astroglial Function After Intracerebroventricular Infusion of Methylglyoxal in RatsNeurochemical Research, 2020
- Repeated Methylglyoxal Treatment Depletes Dopamine in the Prefrontal Cortex, and Causes Memory Impairment and Depressive-Like Behavior in MiceNeurochemical Research, 2019
- Diabetes Mellitus as a Risk Factor for Parkinson’s Disease: a Molecular Point of ViewMolecular Neurobiology, 2018
- Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson’s diseaseNaunyn-Schmiedeberg's Archives of Pharmacology, 2018
- Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration studyBrain Research, 2017
- Protein degradation pathways in Parkinson’s disease: curse or blessingActa Neuropathologica, 2012
- Behavioral phenotyping of mouse models of Parkinson's diseaseBehavioural Brain Research, 2010
- Behavioral alterations in rotenone model of Parkinson's disease: Attenuation by co-treatment of centrophenoxineBrain Research, 2008
- Behavioral models of Parkinson's disease in rodents: A new look at an old problemMovement Disorders, 2006